Chemoembolization vs. Radioembolization for Liver Cancer: Key Differences and Survival Outcomes

Chemoembolization (TACE) and radioembolization (TARE) are two leading treatments for liver cancer, especially hepatocellular carcinoma (HCC). Both approaches target tumors directly while protecting healthy liver tissue, but each has unique benefits depending on stage, tumor size, and liver function. This episode breaks down how they work, who benefits most, and what research says about their effectiveness.In this episode, you’ll learn:How chemoembolization delivers chemotherapy directly to liver tumorsWhat makes drug-eluting bead TACE (DEB-TACE) more effective for small tumorsWhy is radioembolization safer when the portal vein is blockedWhich treatment offers better control for large or multiple liver tumorsThe main differences in side effects between TACE and radioembolizationWhat clinical trials reveal about survival outcomes and long-term resultsWhen doctors switch patients from TACE to radioembolization for a better responseThis episode gives patients and families a clear comparison of liver cancer treatment options, helping them understand the right approach for their specific situation.Blog Link: Chemoembolization for Liver CancerSend us Fan MailThank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.Author: Dr. CHRISTINA NG VAN TZE📍 Visit us at oncolifecentre.com 📞 Call: +60 3 2242 3260 📧 Book a consultation or ask a question — we're here to support your journey.